Generic Claritin-D
This article was originally published in The Tan Sheet
Executive Summary
Andrx receives tentative FDA approval July 9 for 24-hour loratadine/pseudoephedrine combination. Generics company is believed to be first to file an ANDA for equivalent to Schering-Plough's Claritin-D 24-Hour; Impax Labs was first to file for 12-hour formulation and has entered into contract manufacturing, supply agreement with Schering for OTC distribution (1"The Tan Sheet" July 1, 2002, p. 4). Andrx, Impax are defendants in Schering's ongoing patent litigation. Separately, Schering announces July 8 approval in Japan for Rx sale of Claritin 10 mg tablets...
You may also be interested in...
Claritin in Japan
Schering-Plough's Japanese subsidiary will launch RediTabs imminently, the firm announces. The product is "the first and only allergy product in Japan designed to orally disintegrate," Schering says. The Rx drug's indications mirror those for use in the U.S. The Japanese Ministry of health cleared Claritin for prescription status in 2002 (1"The Tan Sheet" July 15, 2002, In Brief)...
Impax, Schering Patent Litigation Continues Despite Claritin-D Agreement
Impax Labs' agreement to supply Schering-Plough with Claritin-D 12-Hour for OTC sale is not expected to attract Federal Trade Commission scrutiny due to its nonexclusivity provisions and lack of impact on pending patent litigation, the generics firm said
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.